Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-016275
Filing Date
2022-11-03
Accepted
2022-11-03 16:31:12
Documents
47
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nxtc-20220930x10q.htm   iXBRL 10-Q 1141251
2 EX-31.1 nxtc-20220930xex31d1.htm EX-31.1 12904
3 EX-31.2 nxtc-20220930xex31d2.htm EX-31.2 12685
4 EX-32.1 nxtc-20220930xex32d1.htm EX-32.1 12261
  Complete submission text file 0001558370-22-016275.txt   4431481

Data Files

Seq Description Document Type Size
5 EX-101.SCH nxtc-20220930.xsd EX-101.SCH 22811
6 EX-101.CAL nxtc-20220930_cal.xml EX-101.CAL 34648
7 EX-101.DEF nxtc-20220930_def.xml EX-101.DEF 88179
8 EX-101.LAB nxtc-20220930_lab.xml EX-101.LAB 267332
9 EX-101.PRE nxtc-20220930_pre.xml EX-101.PRE 178654
41 EXTRACTED XBRL INSTANCE DOCUMENT nxtc-20220930x10q_htm.xml XML 807673
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38905 | Film No.: 221358549
SIC: 2834 Pharmaceutical Preparations